A Center of Excellence for Biomedical Research and Training in Africa
  
  

Clinical challenges faced in Zimbabwe

  1. Late diagnosis and initiation of ART.
  2. Delayed switching to 2nd line ART amongst 1st line failures due to limited access to viral load testing.
  3. Thus, patients remain on failing regimens, allowing the development of extensively resistant viral strains
  4. This may foster the transmission of drug resistant virus: vertical and horizontal

 

Meeting the Resistance Testing needs- Our Solutions

  1. VL tests that monitor virologic suppression and provide early indication of treatment failure
  2. Affordable and timely genotypic drug resistance testing
  3. Identification of key drug resistance mutations that can guide clinical treatment and patient management
  4. Recommendations for new drug classes; who will require Integrase strand transfer inhibitors (INSTIs)  such as Elvitegravir, Raltegravir or Dolutegravir?

 

Guidelines for ART & HIV-DR Testing recommendations

  1. Annual VL is the preferred monitoring approach to identify ART failure
  2. If virologic suppression is not achieved (VL > 1,000 copies/ml) a second test is recommended in 4-6 weeks after adherence counseling.
  3. ART naive patients should be screened for transmitted Drug resistance upon diagnosis and initiation of therapy (optional)
  4. Children/ infants exposed to PMTCT should be screened for transmitted Drug resistance (optional)
  5. HIV-DR testing before switching drug regimens for patients with virological failure on first-line ART (Viral loads >1000 copies/ml) (optional)
  6. HIV-DR testing before switching drug regimens for patients with virological failure on second-line ART (Viral loads >1000 copies/ml) (recommended)

 

Viral load testing

The test itself measures the amount of the HIV virus that is present in a person’s blood. Lower amounts of virus means improved health outcomes for a patient as well as less of a chance to transmit HIV to others. When on ART, viral load testing provides a clear picture of whether a patient is responding successfully to HIV treatment.

Treatment failure is defined as detectable VL>1000 c/ml, i.e. two consecutive VL within 3 month interval with adherence support between measurements after 6 months of using ARV”

pic1

 

Cobas Ampliprep Taqman analyzer machine is used for HIV-VL monitoring assays at Newlands Clinic. With a 3-day turnaround time, this machine yields high precision and sensitive results. LOD <20 copies/ml 2

 

 

pic2

 

 

 

Understanding VL
VL<50 cps/ml Suppressed
VL 50 to 1000 cps/ml Low level Viremia
VL>1000 cps/ml High level Viremia

Cepheid has developed a new test for viral load monitoring. The Xpert HIV-1 Viral Load determines viral load from plasma with a turnaround time of 90mins. LOD from plasma is <20 copies/ml, LOQ from plasma 40cps/ml 3,4.

 

Why does HIV- Drug resistance occur?

HIV replicates its genome with the highest known mutation rate of any living organism. The replication in the absence of any enzymatic proofreading activity is extremely error prone resulting in one mistake on average in every viral genome transcribed.  This creates a complex mix of viral quasi-species.

Drugs exert pressure that selects mutations allowing quasi-species (which are resistant to drugs) to develop and expand. If treatment is stopped the wild type virus will re-emerge. Drug resistance occurs by two major pathways. The first pathway is by the transmission of drug resistant virus from a partner or from mother to child and is called primary or transmitted drug resistance (TDR).

Secondary or acquired drug resistance is the other major pathway due to which drug resistance develops. This type of resistance occurs when HIV continues to replicate in the presence of suboptimal levels of ART. Factors such as; rapid clearance, poor absorption, host genetics, drug interactions etc. contribute to insufficient drug levels in the body and thus suboptimal therapy5.

HIV & TB Drug Resistance & Clinical Management Case Book

 

Development of Drug Resistance

pic3

 

HIV-DR testing

It is a genotypic test that detects presence/ absence of mutations in a virus population by identifying codon changes at specific sites known to cause resistance. This helps to guide clinical decisions in the use of ARVs for patient management. Here is the laboratory workflow for HIV genotypic drug resistance testing.

Resistance Data + ART History = Effective ART Administration

 

Genotypic testing workflow

pic4

Citation: Monogram Biosciences- HIV Genotypic Tests7

 

 

Example of the HIV-DR Result form

pic5 pic6 pic7

 

Studies that have determined HIV-drug resistance mutations in different cohorts

An on going study at Newlands Clinic, on 2nd line virologic failures (n=92) has found 89% prevalence of NNRTI resistant mutations. Most common ones being K103N and Y181C. 76% of study participants had at least 1 NRTI mutation; M184V and K65R mutations were most predominant. 49% showed to have developed Thymidine  analog mutations (TAMs). PI mutations that confirm second line failure were not as common, and were seen in only 13% of the study group. This helped to deduce treatment failure was due to poor adherence 8.

An adherence intervention trial at a public health clinic was conducted on adolescents failing 2nd line treatment 9. Characterization of drug resistant mutations was carried out on 20 study participants who failed to achieve virologic suppression after 3 months of adherence counseling. PI and NNRTI resistance was seen in 30% and 80% of adolescents respectively. Only 2 of the 20 participants had mutations conferring tenofovir resistance. Although a small sample size this may be indicative of HIV-DR trends among adolescents.

 

How to get VL testing and HIV-DR testing

  1. Visit Newlands Clinic
  2. Get whole blood drawn
  3. Submit the Request form filled out by the physician
  4. Make payment
  5. Collect/receive by email VL results within 3 days
  6. Collect/ receive by email HIV-DR results within 3 weeks

NB.: The VL should be at least 1000 copies/ml for HIV-DR testing

Contact:

Newlands Clinic
56 Enterprise Road, Newlands, Harare
Phone +263-4-776433
info@newlandsclinic.org.zw

Biomedical Research and Training Institute
No. 10 Seagrave road
Mount Pleasant, Harare, Zimbabwe
Phone: +263-4-333091 ; 335641; 333464 ; 336691
makamureb@gmail.combhavinivaryani@gmail.comkvinie2005@yahoo.fr

 

References:

  1. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, National institute of health. https://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_6.pdf
  2. COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0, Roche.
  3. Cephied, Xpert HIV-1 Viral load Datasheet- CEIVD
  4. Ceffa, S., Luhanga, R., Andreotti, M., Brambilla, D., Erba, F. et, 2016, Comparison of the Cepheid Gene Xpert and Abott M2000 HIV-real time molecular assays for monitoring HIV-1 viral load and detecting HIV infection. Journal of Virological Methods. 229, p.35-29.
  5. Rossouw,T,, Lessells, R. and Oliveira, T. 2013, HIV & TB Drug Resistance & Clinical Management Case Book. MRC council. http://www.bioafrica.net/manuscripts/HIVTB_book_chapter1_HIVresistance.pdf
  6. NAM, AidsMap. Information Booklet. http://www.aidsmap.com/What-is-drug-resistance/page/1327026/
  7. Monogram Biosciences, HIV Genotypic test http://www.monogrambio.com/hiv-tests/genotypic-assays
  8. Dr. Chembetete, Newlands Clinic
  9. Chawana, T.D., Ngara, B., Katzenstein, D., Nathoo, K. and Nhachi, C.F.B. Adolescent Treatment Failure (ATF) study. An adherence intervention and drug resistance among HIV positive adolescents failing 2nd line treatment at a public health clinic- a randomized controlled trial.

Additional reading:

  1. https://aidsinfo.nih.gov/education-materials/fact-sheets/21/56/drug-resistance
  2. http://www.nac.org.zw/sites/default/files/2013%20Zimbabwe%20ARV%20Guidelines%20%20Main%20Document%20(1).pdf
  3. http://www.bioafrica.net/manuscripts/HIVTB_book_chapter1_HIVresistance.pdf

Clinical Trials


Our Future

With the contributions from a dedicated and professional staff complement, BRTI has achieved  20 years of continuing growth. From its inception in 1995, the BRTI has strived to become a a centre for excellence in health research and training in Africa. We are confident that the philosophy behind the formation of BRTI, that African scientists must take responsibility for improving their own working environment, was correct. We predict that, in spite of a degree of economic uncertainty in Zimbabwe, the gains that have been made during these years can be consolidated and expanded. We look forward to the future with confidence.

Partner with US






Laboratory Services Offered




ISO 15189 Certified


Online Resources